Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab' - sprookjes - yvandenbroek - TriplyDB

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

http://www.wikidata.org/entity/Q34125254

about

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Rituximab for rheumatoid arthritis Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature Understanding the role of B cells in atherosclerosis: potential clinical implications Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Combination therapy with biologic agents in rheumatic diseases: current and future prospects Rituximab for Rheumatoid Arthritis.Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.B cells and atherosclerosis.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.Decision tool to improve the quality of care in rheumatoid arthritis Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis Rituximab in the treatment of pemphigus vulgaris.Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow.Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.Rituximab for the treatment of rheumatoid arthritis: an update.

P2860

Q24185797-F1E68CF1-71D9-433E-8C93-9DA66959D656 Q24186568-11F372EB-980C-4C95-933B-144EE51EED28 Q26773161-8ADC2DF8-32B1-4223-8433-58F1E73F226E Q26798526-BB6F70A5-3EEF-4C01-8D32-311988273024 Q26991813-FCDA698A-D602-445E-93D4-F9DD65F9856F Q27691388-0EF5A7E3-5152-49D3-8DC5-FC8AB7EA8AF4 Q28066250-235CC057-BE02-4A4B-8F92-9433B14D231F Q28080246-46D9644A-CB5E-4526-8645-B95F34323490 Q28547851-CA5AF63A-718C-466F-8932-E6CA3814908D Q28551075-65978E97-46DA-4410-AD4C-5925F5AC21E3 Q30234528-5017977B-42DA-4CB5-8412-B8A3E8E401B3 Q30235341-19BA3F62-AA2C-4A1E-9FAA-1643A19B395F Q30252928-C4BF3F15-0FF8-46AF-846A-1E479D239C54 Q31046441-5C31F1B4-03B0-4B32-8550-332F28E27F52 Q33421410-26F4AD65-B9D4-4404-98DD-54EC2F895E32 Q33672391-15F9E031-15E4-47A0-A00E-35A0F86D08C9 Q33809045-A1C0BE71-A5A6-42B4-8AC7-CE0B5A53863C Q34500502-1F439A08-9299-4FC4-9B92-031D320BD29A Q34523450-66CBD1A6-4C54-4A40-AED9-4BD4C198B6D8 Q34810094-7934F3CF-0306-4A0C-9C67-903F8BFDDDFF Q34975404-BA1A71D6-B165-4EEC-A2E8-DEB1A8B30D6E Q35540009-ECFDC943-00F1-4927-A56F-EF053DCCCB02 Q35557832-45AA9127-EE01-424B-829F-F759FDFC8980 Q35569500-ED858985-0FDE-487B-B736-1EA227E72866 Q35662575-B18E96CF-7693-4C17-AF6A-AFECE1AB58EB Q35751550-6D163BAB-68EE-46DD-9FD9-77586AA5C74D Q36005609-A50E0B8E-E334-49B6-B65E-AFD89A7B7639 Q36032715-920B8FCF-1CE3-427F-AB4B-F4C89FC7F6AE Q36060036-68A5C042-6E8F-4712-B760-63ACEA3A3F0A Q36195284-2F5CC1EC-B3FA-4FFE-9FC6-B95546F6D1F6 Q36219954-B3512EDC-2988-48A1-9511-AB24A6FAB492 Q36434853-15477490-0F33-4DC6-85CA-8353F93D4CEE Q36503878-69FB068D-A032-4CB9-BCE5-EFA8EF03EC04 Q37085663-A54A4016-ABAD-46ED-B0C1-7D4D5EC31E14 Q37130018-2C5C0E59-07DD-437F-8EBF-6F9DD0513BB8 Q37326017-75F4EDCE-D535-41CD-A000-333D74BBF2DD Q37358271-0292D4A6-A2E3-4ADC-8779-329BC792208B Q37388213-DD517B50-2E99-4E63-8D6F-4C5FA3501399 Q37424048-50007192-E539-4DB1-BDCA-79E217E99B3C Q37444678-BF1ECAFF-6304-42F3-948F-5311DDC3BCF1

P2860

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

http://www.wikidata.org/entity/Q34125254

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@ast

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en-gb

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@nl

type

label

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@ast

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en-gb

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@nl

prefLabel

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@ast

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en-gb

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@nl

P1433

Q34125254-F41D1B87-2EEA-4A32-B752-0377710ACB4B

P1476

Q34125254-7552224A-34C3-4397-BA19-65773BE0511D

P2093

Q34125254-2C96AD54-0249-4B9D-B5B0-95B1F83BD706

Q34125254-43AFD679-ECDF-4950-B5EE-67EBD81ED9AF

Q34125254-69914A03-D261-4920-B36D-83B192C413E1

Q34125254-861A0730-8771-4C86-96C8-0F1D8300E49F

Q34125254-901ABC3B-E39A-4BDA-B686-16DB4EA5A472

Q34125254-9A2ECF9F-EEE7-4916-B29E-BC1C01EFCB6A

Q34125254-A8B9516D-811D-4893-AF7B-45A12F84B785

Q34125254-C5946E9C-9D0A-44B8-B4A6-2299504A426A

Q34125254-D94FB437-71C0-416E-9375-220D78D041D6

Q34125254-EC0A717B-8CDE-4D41-9363-A45D5F1F9D7C

P2860

Q34125254-1B3CB075-81C8-4F8F-84C6-373AB5EBDF27

Q34125254-65E5D5FE-6B4E-4DB9-8C16-8A935995A544

Q34125254-96C6836B-8289-4A42-AC70-9FE0CD874655

Q34125254-A26B3533-D225-43FC-9BC9-F374FF2ECC3A

Q34125254-AB7A3B00-5077-4CE0-B37F-4415D378CAEE

Q34125254-BDBB0B4F-69E8-4FF0-8541-38D424E862A2

Q34125254-DEA260F5-A8CE-465C-86A7-3AF16C5DDF91

Q34125254-FFE304B5-27F7-45C9-B044-9C649E5C9B93

P304

Q34125254-D451212D-70ED-4B23-8879-43CE132B6DEE

P31

Q34125254-ECDC77D3-1B21-436B-8471-411CC7BF3C14

P356

Q34125254-E275A83E-86FB-4772-8A1A-A3B9F21B8369

P407

Q34125254-002CEA83-D5DE-410C-9480-BC4FCD61B082

P433

Q34125254-B4FEAB06-2D75-46E4-B029-B11267810266

P478

Q34125254-E8E386D5-8C9A-4474-89B3-DCFBC1FBA4D7

P50

Q34125254-C9023EDD-F23E-48F6-A2A8-B33308413E52

P577

Q34125254-F0905830-33EF-4CB3-9FC7-BC62733E7CB2

P5875

Q34125254-74C284FF-33EA-4479-9852-CA62E19C9B0C

P6179

Q34125254-65910891-AF1C-49B8-8939-1A1C90D298F0

P698

Q34125254-220176A0-2810-4773-BE7E-A67EB2C9FE34

P921

Q34125254-9D1F6E05-7B0C-4D62-8361-96AA7BB80F54

Q34125254-9F60E279-779D-48EB-B454-6ED93D1F801E

P932

Q34125254-DC5D45A4-917A-4608-A047-CA67F741A10F

P356

ARD.2009.119933

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy and safety of differe ...... e (Study Evaluating Rituximab'

@en

P2093

A Chen

http://www.w3.org/2001/XMLSchema#string

A Deodhar

http://www.w3.org/2001/XMLSchema#string

A J Racewicz

http://www.w3.org/2001/XMLSchema#string

B Combe

http://www.w3.org/2001/XMLSchema#string

C Abud-Mendoza

http://www.w3.org/2001/XMLSchema#string

G K Armstrong

http://www.w3.org/2001/XMLSchema#string

H Tyrrell

http://www.w3.org/2001/XMLSchema#string

J D Isaacs

http://www.w3.org/2001/XMLSchema#string

K Latinis

http://www.w3.org/2001/XMLSchema#string

L J Szczepanski

http://www.w3.org/2001/XMLSchema#string

P2860

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis.

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

P304

1629-1635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2009.119933

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44617442

http://www.w3.org/2001/XMLSchema#string

P6179

1042078446

http://www.w3.org/2001/XMLSchema#string

P698

20488885

http://www.w3.org/2001/XMLSchema#string

P921

P932

2938895

http://www.w3.org/2001/XMLSchema#string